One device. Every parameter. 60 seconds.
TearScan is a tabletop diagnostic instrument that measures all critical tear film parameters in a single, automated test. No more juggling four devices. No more incomplete diagnoses.
The Problem
Today's dry eye diagnosis is fragmented across multiple instruments, each measuring only a fraction of the tear film. Clinicians are forced to piece together an incomplete picture.
$5,000 - $8,000
Osmolarity only. One parameter from one eye at a time.
$15,000 - $30,000
Meibography and NIBUT only. No osmolarity, no lipid layer quantification.
$5,000 - $10,000
Lipid layer imaging only. Cannot measure osmolarity or gland structure.
$15 per test
MMP-9 inflammation marker only. No imaging, no quantification.
The Device
TearScan is a compact tabletop instrument roughly the size of a small desktop printer. With an integrated chinrest, display screen, and three measurement modules, it delivers a complete tear film profile without the patient ever leaving the chair.
Patient Workflow
Zero added chair time. A complete tear film diagnostic in four effortless steps.
Load a single-use microfluidic cartridge into the device. Takes 2 seconds.
Patient places chin on rest, just like a slit lamp exam. Familiar and comfortable.
TearScan runs all six measurements automatically. No technician interaction needed during the test.
Complete tear film profile with AI-powered DED classification delivered in 60 seconds.
What It Measures
Every clinically significant tear film metric, measured simultaneously from a single patient interaction.
Gold-standard biomarker for dry eye disease. TearScan's microfluidic sensor requires just 50 nanoliters of tear fluid collected via a disposable cartridge, measuring osmolarity with laboratory-grade accuracy at the point of care.
Quantifies the outermost protective lipid layer of the tear film. Thin or absent lipid layers are the hallmark of evaporative dry eye, the most common subtype. Measured non-invasively via spectral interferometry.
Non-contact infrared imaging reveals the morphology of meibomian glands in both upper and lower eyelids. Detects gland dropout, truncation, and dilation that indicate meibomian gland dysfunction (MGD).
Measures tear film stability by tracking the time to first break-up without fluorescein dye. Projected ring patterns on the cornea detect tear film disruption with sub-second precision, eliminating observer bias.
Precisely measures the tear meniscus along the lower lid margin. Low meniscus height is an indicator of aqueous-deficient dry eye, helping differentiate between DED subtypes for targeted treatment.
Proprietary AI model integrates all six measurements to classify dry eye disease as evaporative, aqueous-deficient, or mixed. Provides a confidence-scored diagnosis aligned with the TFOS DEWS II framework, guiding personalized treatment.
Competitive Comparison
No other instrument on the market delivers a complete tear film profile. TearScan is the first.
| Parameter | TearScan | TearLab | Keratograph 5M | LipiView II | InflammaDry |
|---|---|---|---|---|---|
| Tear Osmolarity | × | × | × | ||
| Lipid Layer Thickness | × | × | × | ||
| Meibomian Gland Imaging | × | × | × | ||
| Non-Invasive TBUT | × | × | × | ||
| Tear Meniscus Height | × | × | × | ||
| AI DED Classification | × | × | × | × | |
| MMP-9 Inflammation | × | × | × | × | |
| Device Cost | $8K - $12K | $5K - $8K | $15K - $30K | $5K - $10K | N/A |
| Per-Test Cost | $15 - $20 | $4 - $6 | $0 | $0 | $15 |
TearScan: 6 of 7 parameters. No other device exceeds 3.
The only all-in-one tear film diagnostic on the market.For Clinicians
Add comprehensive dry eye diagnostics without adding chair time, staff, or complexity.
TearScan slots into your existing exam flow. Patients are already in the chair. The test adds zero additional visit time.
Dry eye testing is well-reimbursed. TearScan's multi-parameter output supports billing across multiple established CPT codes.
At 8-12 tests per day, TearScan pays for itself in 3-6 months. Ongoing consumable revenue is margin-positive from day one.
Clinical Science
TearScan's diagnostic framework is built on the gold-standard Tear Film & Ocular Surface Society guidelines for dry eye disease classification.
Dry eye disease is not a single condition. The TFOS DEWS II report established that effective treatment requires identifying the specific subtype: is the tear film evaporating too quickly, or is the body not producing enough tears? Most patients present with a combination of both.
TearScan is the first point-of-care device that captures enough tear film data to classify DED subtype automatically, enabling targeted rather than empirical treatment.
Caused by meibomian gland dysfunction. Identified by thin lipid layer, short TBUT, and gland dropout on meibography. The most common subtype, affecting up to 86% of DED patients.
Insufficient tear production from the lacrimal gland. Characterized by low meniscus height, elevated osmolarity, and intact lipid layer. Associated with autoimmune conditions such as Sjogren's syndrome.
Features of both evaporative and aqueous-deficient disease. The most common clinical presentation. Requires multi-modal treatment targeting both lipid layer and aqueous volume.
Multi-center prospective study design comparing TearScan measurements against established predicate devices (TearLab, Keratograph 5M, LipiView II) in a cohort of DED patients and age-matched controls. Primary endpoints: measurement concordance, diagnostic sensitivity/specificity, and DED subtype classification accuracy versus expert panel consensus.
Regulatory & Trust
TearScan is designed from the ground up to meet the regulatory, quality, and security requirements of clinical diagnostics.
Pursuing clearance via the 510(k) pathway with established predicate devices including TearLab osmolarity system and OCULUS Keratograph.
All patient data encrypted at rest (AES-256) and in transit (TLS 1.3). No cloud dependency for device operation. Optional secure EMR sync.
Quality management system designed to ISO 13485 standards for medical devices. Full design history file, risk management per ISO 14971.
Multi-center prospective clinical study protocol with IRB oversight. Designed to demonstrate equivalence to predicate devices and superior diagnostic utility.
Pricing
The cost of one TearLab plus one LipiView. The diagnostic capability of all four devices combined.
Replace $35,000 - $60,000 in separate devices for under $12,000.
At 10 tests per day with standard reimbursement, the device pays for itself within 4 months.Get Started
Schedule a live demonstration to see TearScan's complete tear film analysis. We will walk you through the device, the clinical workflow, and the economics for your practice.